Menopause: Developing a rational treatment plan

Gynecological Endocrinology

Volumn 23, Issue 12, 2007, Pages 682-691

  Vitiello, Danielle ^a   Naftoilin, Frederick ^b   Taylor, Hugh S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Menopausal hormone therapy; Menopause

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; AROMATASE; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; CHEMOKINE RECEPTOR CCR1; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYTOCHROME P450; CYTOCHROME P450 1B1; D DIMER; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEURONAL THREAD PROTEIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; PRESENILIN 1; PRESENILIN 2; PROTEIN; PROTEIN P97; PROTHROMBIN; TAU PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON WILLEBRAND FACTOR;

ALZHEIMER DISEASE; ATTITUDE; BONE MASS; BREAST CANCER; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COPING BEHAVIOR; DRUG EFFICACY; HEART INFARCTION; HIP FRACTURE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; SOCIAL ASPECT; STROKE; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ATTITUDE TO HEALTH; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; DECISION MAKING; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEMOSTASIS; HUMANS; MENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 37149053208     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590701690597     Document Type: Review

References (77)

1. Barnabei VM, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002;100(6):1209-1218.
2. Greendale GA, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92(6):982-988.
3. Keating NL, et al. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130(7):545-553.
4. Hersh A, Stefanick M, Stafford R. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291(1):47-53.
5. CDC. Incidence and costs to Medicare of fractures among Medicare beneficiaries aged465 years - United States (July 1991-June 1992). MMWR 1996;45:877-883.
6. Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 2002;53(3):550-557.
7. PEPI. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273(3):199-208.
8. Hulley S, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280(7):605-613.
9. Cherry N, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002;360(9350):2001-2008.
10. Writing Group for the Women's Health Initiative Investigators. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-333.
11. Hsia J, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166(3):357-365.
12. Herrington DM, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343(8):522-529.
13. Waters DD, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288(19):2432-2440.
14. Hodis HN, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349(6):535-545.
15. Hodis HN, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135(11):939-953.
16. Harman S, Brinton E, Cedars M, Lobo R, Manson J, Merriam G, Miller V, Naftolin F, Santoro N. KEEPS: The Kronos Early Estrogen Prevention Study. Climateric 2005;8(1):3-12.
17. Evangelopoulos D, et al. Molecular analysis of the estrogen receptor alpha gene in men with coronary artery disease: association with disease status. Clin Chim Acta 2003;331(1-2):37-44.
18. Kunnas TA, et al. Association of polymorphism of human alpha oestrogen receptor gene with coronary artery disease in men: a necropsy study. BMJ 2000;321(7256):273-274.
19. Lehtimaki T, et al. Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study. J Mol Med 2002;80(3):176-180.
20. Matsubara Y, et al. Genotype distribution of estrogen receptor polymorphisms in men and postmenopausal women from healthy and coronary populations and its relation to serum lipid levels. Arterioscler Thromb Vasc Biol 1997;17(11):3006-3012.
21. Petrovic D, Peterlin B. Estrogen receptor dinucleotide (TA) polymorphism does not predict premature myocardial infarction in Caucasian women. Cardiology 2003;99(3):163-165.
22. Shearman AM, et al. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 2003;290(17):2263-2270.
23. Moniek P, deMaat M, Madsen J, Langdahl B, Bladbjerg E, Tofteng C, Abrahamsen B, Rejnmark L, Brixen K, Christensen K, Jespersen J, Kristensen S. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammatory markers after longterm hormone replacement therapy. Thrombosis and Haemostasis 2007;97(2):234-239.
24. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Jarvinen H. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal woman. Thrombosis and Haemostasis 2001;85(4):619-625.
25. Koh KK, et al. Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women. Am J Cardiol 1999;83(3):466-469, A10.
26. Manson JE, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349(6):523-534.
27. Psaty BM, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001;285(7):906-913.
28. Shlipak MG, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000;283(14):1845-1852.
29. Gebara OC, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995;91(7):1952-1958.
30. Baker L, et al. The role of estrogen in cardiovascular disease. J Surg Res 2003;115(2):325-344.
31. Oian P, Osterud B. Monocyte-platelet function and protection against cardiovascular disease. Maturitas 1996;23(Suppl):S57-S60.
32. Nelson HD, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288(7):872-881.
33. Daling JR, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 2002;95(12):2455-2464.
34. Daling JR, et al. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. Cancer Epidemiol Biomarkers Prev 2003;12(11 Pt 1):1175-1181.
35. Li CI, et al. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000;88(11):2570-2577.
36. Newcomer LM, et al. Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 2003;14(3):225-233.
37. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344(4):276-285.
38. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362(9382):419-427.
39. Stefanick ML, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295(14):1647-1657.
40. Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med 2003;163(18):2149-2153.
41. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet 2004;363(9407):453-455.
42. Sellers TA, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997;127(11):973-980.
43. Cauley JA, et al. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122(1):9-16.
44. Maxim P, Ettinger B, Spitalny GM. Fracture protection provided by long-term estrogen treatment. Osteoporos Int 1995;5(1):23-29.
45. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285(22):2891-2897.
46. Ralston SH. Genetic determinants of susceptibility to osteoporosis. Curr Opin Pharmacol 2003;3(3):286-290.
47. Morrison NA, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994;367(6460):284-287.
48. Cooper GS, Umbach DM. Are vitamin D receptor polymorphisms associated with bone mineral density? A metaanalysis. J Bone Miner Res 1996;11(12):1841- 1849.
49. Graafmans WC, et al. The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype. J Bone Miner Res 1997;12(8):1241-1245.
50. Garcia-Giralt N, et al. Two new single-nucleotide polymorphisms in the COL1A1 upstream regulatory region and their relationship to bone mineral density. J Bone Miner Res 2002;17(3):384-393.
51. Weel AE, et al. Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab 1999;84(9):3146-3150.
52. Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev 2003;24(2):133-151.
53. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res 2002;57:357-384.
54. Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985;89(2):484-490.
55. Yaffe K, et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998;279(9):688-695.
56. Henderson VW, et al. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994;51(9):896-900.
57. Tang MX, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348(9025):429-432.
58. Grady CL, Craik FI. Changes in memory processing with age. Curr Opin Neurobiol 2000;10(2):224-231.
59. Matthews K, et al. Estrogen replacement therapy and cognitive decline in older community women. J Am Geriatr Soc 1999;47(5):518-523.
60. Shumaker SA, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289(20):2651-2662.
61. Shumaker SA, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291(24):2947-2958.
62. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353- 356.
63. Turner RS. Biomarkers of Alzheimer's disease and mild cognitive impairment: are we there yet? Exp Neurol 2003;183(1):7-10.
64. Richette P, Corvol M, Bardin T. Estrogens, cartilage, and osteoarthritis. Joint Bone Spine 2003;70(4):257-262.
65. Mascarenhas P, et al. Influence of sex hormones on the periodontium. J Clin Periodontol 2003;30(8):671-681.
66. Paganini-Hill A. The benefits of estrogen replacement therapy on oral health. The Leisure World cohort. Arch Intern Med 1995;155(21):2325-2329.
67. Sumino H, Ichikawa S, Abe M, Endo Y, Ishikawa O, Kurabayashi M. Effects of aging, menopause, and hormone replacement therapy on forearm skin elasticity in women. J Am Geriatr Soc 2004;52(6):945-949.
68. Ashcroft GS, Ashworth JJ. Potential role of estrogens in wound healing. Am J Clin Dermatol 2003;4(11):737-743.
69. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8(11):1323-1327.
70. Petricoin EF, et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002;1(9):683-695.
71. Schneider HP. The quality of life in the post-menopausal woman. Best Pract Res Clin Obstet Gynaecol 2002;16(3):395-409.
72. Bravata DM, Rastegar A, Horwitz RI. How do women make decisions about hormone replacement therapy? Am J Med 2002;113(1):22-29.
73. Fisher WA, et al. Canadian menopause study-I: Understanding women's intentions to utilise hormone replacement therapy. Maturitas 2000;37(1):1-14.
74. O'Connor AM, et al. Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventive hormone therapy. Med Decis Making 1998;18(3):295-303.
75. Woods NF, et al. Deciding about hormone therapy: validation of a model. Menopause 1998;5(1):52-59.
76. Zubialde JP, Lawler F, Clemenson N. Estimated gains in life expectancy with use of postmenopausal estrogen therapy: a decision analysis. J Fam Pract 1993;36(3):271-280.
77. Schapira MM, et al. Menopausal hormone therapy decisions: insights from a multi-attribute model. Patient Educ Couns 2004;52(1):89-95.